Education
About Us
Working with TipRanks
Follow Us
Mesoblast Ltd (MESO)
NASDAQ:MESO
Earnings Data
Report Date
Feb 26, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.23Last Year’s EPS
-0.42Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call illustrated significant growth and successful product launch achievements, particularly with Ryoncil's market penetration and FDA approval. However, increased operational expenses and revaluation-related losses presented financial challenges. Overall, the company's positive strides in market access and regulatory feedback indicate strong potential for future growth.Company Guidance
Record Revenue Growth
Revenue from cell therapy products reached $17.2 million, up 191% from the prior year, driven by the successful launch of Ryoncil.
Successful Launch of Ryoncil
Ryoncil, the first and only FDA-approved MSC therapy, launched successfully with 32 transplant centers onboarded and coverage for over 250 million lives in the U.S.
Strong Market Access for Ryoncil
Ryoncil is covered by insurance plans representing over 250 million lives, with Medicaid coverage in all states as of July 1.
Promising FDA Feedback for Heart Failure Therapy
FDA indicated support for an accelerated approval pathway for Revascor in heart failure, based on existing data and a planned confirmatory trial.
J-Code Issued for Ryoncil
A specific J-Code for Ryoncil is set to go into effect on October 1, allowing for more efficient billing and reimbursement processes.
MESO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MESO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 28, 2025 | $15.95 | $13.83 | -13.29% |
May 28, 2025 | $10.97 | $10.95 | -0.18% |
Feb 26, 2025 | $15.72 | $15.54 | -1.15% |
Nov 20, 2024 | $10.82 | $10.33 | -4.53% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Mesoblast Ltd (MESO) report earnings?
Mesoblast Ltd (MESO) is schdueled to report earning on Feb 26, 2026, TBA (Confirmed).
What is Mesoblast Ltd (MESO) earnings time?
Mesoblast Ltd (MESO) earnings time is at Feb 26, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MESO EPS forecast?
MESO EPS forecast for the fiscal quarter 2026 (Q2) is -0.23.